Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Sodium lauryl sulfoacetate

Classification: B

Drug products: Microlax®

ATC code: A06AG11

Substances: sodium lauryl sulfoacetate

Summary

Controlled studies on differences between men and women in sodium lauryl sulphate efficacy and safety are lacking
.
 
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of sodium lauryl sulphate have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of sodium lauryl sulphate have been found.

Adverse effects

The skin irritability of volunteers to sodium lauryl sulphate (2% aqueous) has been studied by measuring skin vapour loss (SVL) (23 men, 15 women). The study found that female skin is more easily irritated [1].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2015-08-20

References

  1. Goh CL, Chia SE. Skin irritability to sodium lauryl sulphate--as measured by skin water vapour loss-by sex and race. Clin Exp Dermatol. 1988;13:16-9. PubMed
  2. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson